Alps Advisors Inc. bought a new stake in C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,950 shares of the company’s stock, valued at approximately $218,000. Alps Advisors Inc. owned 0.06% of C4 Therapeutics at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Tortoise Investment Management LLC acquired a new position in shares of C4 Therapeutics in the 1st quarter valued at $45,000. Point72 Hong Kong Ltd boosted its holdings in C4 Therapeutics by 89.7% in the first quarter. Point72 Hong Kong Ltd now owns 3,815 shares of the company’s stock valued at $93,000 after purchasing an additional 1,804 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in C4 Therapeutics in the first quarter valued at $93,000. Fox Run Management L.L.C. purchased a new stake in C4 Therapeutics in the first quarter valued at $217,000. Finally, Hsbc Holdings PLC purchased a new stake in C4 Therapeutics in the first quarter valued at $251,000. 80.43% of the stock is owned by institutional investors and hedge funds.
C4 Therapeutics Stock Down 16.2 %
Shares of NASDAQ CCCC opened at $7.86 on Thursday. The company has a 50 day simple moving average of $9.04 and a 200-day simple moving average of $8.96. The company has a market capitalization of $384.80 million, a P/E ratio of -4.32 and a beta of 1.97. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.19 and a quick ratio of 7.19. C4 Therapeutics, Inc. has a 1 year low of $4.84 and a 1 year high of $38.37.
Analyst Ratings Changes
C4 Therapeutics Profile
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.
- Get a free copy of the StockNews.com research report on C4 Therapeutics (CCCC)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.